About Zilico
Zilico is developing the next generation of cancer diagnostics that will provide real-time diagnosis for cervical cancer and reduce the inherent subjectivity of current methods. Two applications are under development: the first for the referral market and the second for the screening market.
Since incorporation in 2006, Zilico has focused on developing a research-based instrument into a device (system) appropriate for commercial manufacture and routine use by medical practitioners. The Zilico system consists of a handheld device and a base unit together with a single-use disposable sleeve for each test. Clinical data on over 900 women has demonstrated superior performance over existing diagnostic procedures. Zilico completed a pivotal multi-centre trial in 2011.
Zilico will launch the first application in Europe and rest of the world in 2012 and subsequently in the USA. The clinical trials for the second application, scheduled for 2013, will necessarily be larger in scope.